Recent PHVS News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/11/2024 10:52:06 AM
- Pharvaris Announces Annual Meeting of Shareholders • GlobeNewswire Inc. • 06/11/2024 10:50:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/04/2024 08:05:02 PM
- Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses • GlobeNewswire Inc. • 06/04/2024 10:50:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/24/2024 09:04:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/22/2024 09:54:50 PM
- Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses • GlobeNewswire Inc. • 05/13/2024 10:50:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 08:11:03 PM
- Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/08/2024 08:10:00 PM
- Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/10/2024 08:10:00 PM
- Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer • GlobeNewswire Inc. • 04/10/2024 08:08:00 PM
- Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference • GlobeNewswire Inc. • 04/04/2024 10:50:00 AM
- Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses • GlobeNewswire Inc. • 03/18/2024 10:50:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 05:51:18 PM
- Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 03/06/2024 09:40:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2024 09:15:02 PM
- Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses • GlobeNewswire Inc. • 03/06/2024 11:50:00 AM
- Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 • GlobeNewswire Inc. • 03/05/2024 11:50:00 AM
- Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting • GlobeNewswire Inc. • 02/22/2024 11:50:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/16/2024 11:51:04 AM
- Pharvaris Announces Extraordinary Meeting of Shareholders • GlobeNewswire Inc. • 02/16/2024 11:50:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 09:01:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/01/2024 09:46:17 PM
- Pharvaris to Present at the WSAAI Annual Meeting 2024 • GlobeNewswire Inc. • 01/26/2024 11:50:00 AM
- Pharvaris Says FDA Lifted Clinical Hold on Application for Deucrictibant • Dow Jones News • 01/22/2024 12:35:00 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM